Source comparison
Direct Mechanism Comparison
MOTS-c influences metabolic function at the gene expression and mitochondrial level. Its effects on body composition are secondary to improved insulin sensitivity and glucose disposal. Tesofensine produces weight loss through appetite reduction and increased e
This comparison does not assign a generated winner or score.
- MOTS-c influences metabolic function at the gene expression and mitochondrial level. Its effects on body composition are secondary to improved insulin sensitivity and glucose disposal. Tesofensine produces weight loss through appetite reduction and increased energy expenditure via CNS monoamine modulation. The pathways don't overlap. MOTS-c doesn't cross the blood-brain barrier to any meaningful extent; tesofensine doesn't bind mitochondrial DNA or activate AMPK. Comparing them is like comparing metformin to phentermine. Both affect weight, but the how and why are unrelated.
- Primary Mechanism
- AMPK activation, mitochondrial function enhancement, nuclear gene regulation
- Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin)
- Metabolic vs neurochemical pathways
- Site of Action
- Mitochondria, skeletal muscle, nucleus
- CNS synapses (hypothalamus, reward centers)
- Peripheral vs central
- Effect on Appetite
- Minimal to none. Does not suppress hunger signaling
- Significant appetite suppression (primary effect)
- MOTS-c doesn't reduce caloric intake
- Effect on Energy Expenditure
- Improves substrate utilization efficiency, minimal thermogenic effect
- Increases resting energy expenditure via norepinephrine (~5–8% above baseline)
- Tesofensine burns more calories at rest
- Clinical Weight Loss Data
- No direct human weight-loss trials; animal data shows obesity prevention, not reversal
- 10.6% mean body weight reduction at 1.0mg daily over 24 weeks (Phase IIb)
- Tesofensine has human efficacy data
- Regulatory Status
- Research peptide, no FDA approval
- Investigational compound, Phase III trials ongoing, not FDA-approved
- Neither is approved for clinical use